Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-101 in Advanced Ovarian Cancer
NCT07905677Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2029
01
Overview
Phase 1, open-label, single-arm trial of alpha-tocopheryloxyacetic acid in epithelial ovarian cancer (EOC). Primary endpoints: Number of Participants With Dose-Limiting Toxicities and Overall Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
alpha-tocopheryloxyacetic acid
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT07905677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905677.